Bimekizumab (Bimzelx) for Psoriasis
Bimekizumab (Bimzelx) for Psoriasis
January 22, 2024 (Issue: 1694)
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx
– UCB) for treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic
treatment or phototherapy. Bimekizumab is the...more
- JA Singh et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 2019; 71:5. doi:10.1002/art.40726
- A Menter et al. Joint American Academy of Dermatology—National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 2020; 82:1445. doi:10.1016/j.jaad.2020.02.044
- Drugs for psoriasis. Med Lett Drugs Ther 2019; 61:89.
- Deucravacitinib (Sotyktu) for plaque psoriasis. Med Lett Drugs Ther 2023; 65:29.
- K Reich et al. Bimekizumab versus ustekinumab for treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, mutlicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet 2021; 397:487. doi:10.1016/s0140-6736(21)00125-2
- KB Gordon et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet 2021; 397:475. doi:10.1016/s0140-6736(21)00126-4
- RB Warren et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med 2021; 385:130. doi:10.1056/nejmoa2102388
- B Strober et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol 2023; 188:749. doi:10.1093/bjd/ljad035
- K Reich et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med 2021; 385:142. doi:10.1056/nejmoa2102383
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Bimekizumab (Bimzelx) for Psoriasis
Article code: 1694b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
